Developer docs
API playgroundTry for free, no card

Search company profiles

LambdaVision

Full company profile

uuid0000t8k

Namestring
LambdaVision
Legal namestring
LambdaVision, Inc.
Company typeenum
Private
Founded yearint
2009
Descriptiontext

LambdaVision is a privately held, pre-clinical-stage biotechnology company founded in 2009 at the UConn Technology Incubator Program that is developing the first protein-based artificial retina to restore meaningful vision in patients blinded by advanced retinal degenerative diseases, principally retinitis pigmentosa (RP) and, subsequently, age-related macular degeneration (AMD). The company's core technology is a layer-by-layer (LbL) thin-film process that alternates the light-activated protein bacteriorhodopsin with a polymer on a synthetic-fiber membrane to build a 200-layer implant that absorbs incident light and stimulates remaining retinal neural circuitry without requiring external power, electrodes, or bulky hardware. The process is patent-protected (USPTO worldwide patent US20200054441A1) and has been validated across nine missions to the International Space Station in partnership with Space Tango using automated CubeLab hardware, where microgravity conditions deliver superior layer uniformity, optical clarity, and material efficiency versus Earth-based production. The company is led by CEO Nicole L. Wagner, PhD (a UConn co-founder of the technology), CSO Jordan A. Greco, PhD, and founder Dr. Robert R. Birge, with a board that includes seasoned biotech operators and the Connecticut Innovations investor.

LambdaVision has no commercial product and is pre-revenue. Current revenue mechanics consist entirely of non-dilutive grant funding from NASA (SBIR Phase II, InSPA Phase 2, $5M Commercialization Award), the National Science Foundation, the National Eye Institute/NIH, and the Connecticut Bioscience Innovation Fund (~$12M cumulatively from NASA/ISS National Lab), supplemented by priced equity rounds including a 2018 Series A from Connecticut Innovations, a 2024 first seed closing led by Aurelia Foundry Fund, and a $7M seed round in November 2025 co-led by Seven Seven Six and Aurelia Foundry Fund with Seraphim Space, providing stated runway into 2027. Total funding raised to date is approximately $22-23M. Future revenue is expected to come from one-time hardware sales of the artificial retina implant to retinal specialists and academic medical centers (e.g., Yale School of Medicine with Dr. Luciano V. Del Priore as an early clinical champion), with longer-term optionality from licensing the underlying LbL protein film platform for adjacent applications in biosensors, optical systems, tissue engineering, and drug delivery.

The go-to-market motion is a hybrid of strategic co-development partnerships (Space Tango, Helogen, Starlab/Voyager, Vast) for orbital manufacturing and future direct-to-clinical-site field sales for the implant itself, supported by PR/earned media, content marketing, conference presence, and event-driven investor cultivation (CEO speaking at Payload Investors Summit November 2025). To secure post-ISS manufacturing redundancy ahead of the 2030 ISS retirement, the company has pre-booked payload slots on three independent commercial space infrastructure platforms — Starlab Space, Vast's Haven-1 and successors, and Helogen's HEL-IOS — while continuing IND-enabling preclinical studies targeted at advanced retinitis pigmentosa as the first clinical indication and age-related macular degeneration as the second.

Short descriptiontext

LambdaVision is a pre-clinical biotechnology company developing the first protein-based artificial retina, manufactured in microgravity aboard the International Space Station via a patented layer-by-layer bacteriorhodopsin process, to restore vision in patients with retinitis pigmentosa and age-related macular degeneration.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWoodbridge, United States
HQ citystring
Woodbridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
protein-based artificial retina, retinal degenerative diseases, microgravity biomanufacturing, layer-by-layer thin films, bacteriorhodopsin implants
Industry2 codes
PRIMARYHLAHAJAJ
Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAE
Retina & Vitreous Specialists
NAICS code1 code
  • Ophthalmic Goods Manufacturing339115
SIC code1 code
  • Ophthalmic Goods3851
Product category
Ophthalmology Medical Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Non-dilutive government and foundation grants
TypeLicensing Royalties
Description

Pre-clinical funding sourced from NASA (SBIR Phase II, InSPA commercialization awards, ~$12M from NASA and ISS National Lab), the National Science Foundation, and the National Eye Institute/NIH; these funds support preclinical studies, scale-up, and ISS mission costs.

lambdavision.com
2Equity (venture capital) financing
TypeSubscription Recurring
Description

Pre-revenue company; capital is raised through priced equity rounds (notably a $7M seed round co-led by Seven Seven Six and Aurelia Foundry Fund in November 2025, and an earlier Series A from Connecticut Innovations in 2018) used to fund operations through IND-enabling studies and a planned future Series A.

lambdavision.com
3Future product sales of protein-based artificial retina implant
TypeHardware Sales
Description

Planned future commercial revenue from sale of the protein-based artificial retina as a one-time implant to treat advanced retinitis pigmentosa and later age-related macular degeneration, following regulatory clearance and clinical trials.

hartfordbusiness.com
4Future platform licensing for adjacent applications
TypeLicensing Royalties
Description

Longer-term licensing/royalty potential from the LbL protein film platform for biosensors, optical systems, tissue engineering, and drug delivery applications once the core artificial retina is commercialized.

hartfordbusiness.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

LambdaVision develops an investigational protein-based artificial retina implant produced by layer-by-layer deposition of approximately 200 thin films of the light-activated protein bacteriorhodopsin alternating with a polymer on a synthetic-fiber membrane. Manufacturing is conducted in microgravity aboard the International Space Station using Space Tango CubeLab hardware to achieve superior layer uniformity, optical clarity, and material efficiency, with the implant designed to restore meaningful vision in patients blinded by advanced retinitis pigmentosa and age-related macular degeneration.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 9 of 9 ISS missions successfully produced multiple 200-layer protein thin films in microgravity
+4 more records
Product and service1 record
1Protein-Based Artificial Retina (investigational implant for retinitis pigmentosa and AMD)
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Vast
Strategic tierStrategic (Post-Iss Mou)TypeStrategic or Co-development PartnerAnnounced on2026-06-24
Description

Signed a memorandum of understanding on June 24, 2026 with Vast to continue and expand LambdaVision's biomedical research on Vast's Haven-1 and future commercial space stations, after the ISS is retired at the end of the decade. Vast's partner network also includes the Sanford Stem Cell Institute at UC San Diego, Auxilium Biotechnologies, and BioOrbit.

spacenews.com
Strategic tierFlagship (First Mission Outside The Iss)TypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

Strategic partnership announced May 18, 2026 to launch LambdaVision's first orbital manufacturing mission outside the ISS aboard Helogen's fully autonomous HEL-IOS™ manufacturing system in low-Earth orbit, targeted for the second half of 2026. Validates the full operational chain for GMP-compliant production of the artificial retina in LEO, including ground preparation, flight qualification, in-orbit manufacturing, sample return, and custody transfer. Connection initiated through the 2023 Boryung Humans in Space challenge. Helogen also won the 2025 NASA TechLeap Prize.

Strategic tierFlagship (Post-Iss Commercial Manufacturing Anchor)TypeStrategic or Co-development PartnerAnnounced on2026-02-24
Description

Reservation agreement signed February 24, 2026 for payload slots and commercial space on Starlab's next-generation commercial space station. Supports LambdaVision's transition from research demonstration to scalable, sustainable manufacturing in low-Earth orbit ahead of the 2030 ISS retirement. Starlab is a U.S.-led global JV among Voyager Technologies, Airbus, Mitsubishi Corporation, MDA Space, Palantir Technologies, and Space Applications Services, with strategic partners Hilton, Journey, Northrop Grumman, and The Ohio State University.

Strategic tierFlagship (Starlab Lead; Nyse: Voyg)TypeStrategic or Co-development PartnerAnnounced on2026-02-24
Description

Lead joint-venture partner in Starlab Space; partnered with LambdaVision through the Starlab payload reservation announced February 24, 2026 to provide commercial space station access in low-Earth orbit. Seraphim Space is an investor in both LambdaVision and Voyager, enabling portfolio collaboration.

Strategic tierFlagship (Long-Running Implementation Partner)TypeImplementation/ SI/ Consulting Partner
Description

Long-term implementation partner for LambdaVision's ISS missions; provides automated CubeLab hardware on the ISS U.S. National Laboratory. The partnership has secured >$7.7M in funding from NASA and supported all 9 of LambdaVision's ISS investigations refining the LbL manufacturing process. Space Tango is headquartered in Lexington, KY.

6NASA
Strategic tierFlagship (Multi-Program Government Partner)TypeOthers
Description

Long-standing funding and program partner: NASA SBIR Phase II awards, InSPA commercialization awards, the September 2025 Phase 2 InSPA award, and access to the ISS U.S. National Laboratory have collectively provided roughly $12M in non-dilutive funding and 9 ISS missions. NASA's programs underpin LambdaVision's IND-enabling and GMP manufacturing scale-up.

lambdavision.com
Strategic tierStrategic (Clinical Advisor)TypeImplementation/ SI/ Consulting Partner
Description

Clinical research collaboration with Dr. Luciano V. Del Priore, MD, PhD — Robert R. Young Professor of Ophthalmology and Visual Science, Chair of Ophthalmology at Yale School of Medicine, and Chief of Ophthalmology at Yale New Haven Hospital — supporting the artificial retina's preclinical and clinical translation.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pixium Vision developed the PRIMA photovoltaic sub-retinal prosthesis for advanced dry AMD, gaining EU/UK CE marking. It is the most direct retinal implant competitor to LambdaVision, using a different (electronic photovoltaic) mechanism but targeting the same RP/AMD patient population with a surgically implanted retinal prosthesis.

2Second Sight Medical Products (now Nano Precision Medical)
TypeDirect peer
Description

Second Sight developed and commercialized the Argus II epiretinal prosthesis, the first FDA-approved retinal implant for RP. After discontinuing the Argus business, the company refocused as Nano Precision Medical with a drug delivery platform. Argus II is the historical benchmark for retinal prosthesis regulatory and commercial pathways that LambdaVision will be compared against.

TypeDirect peer
Description

Bionic Vision Technologies is an Australian company developing a suprachoroidal retinal prosthesis for patients with retinitis pigmentosa. It is a direct peer because it is pursuing a retinal implant for the same RP indication with a similar surgical implantation approach, though using electrode-based rather than protein-based stimulation.

TypeEmerging player
Description

jCyte is developing a stem cell-based therapy (jCell) for retinitis pigmentosa aimed at preserving and restoring vision through paracrine effects on remaining photoreceptors. It is an emerging peer because it targets the same RP patient population via an alternative mechanism (cell therapy rather than prosthesis) and represents potential competitive pressure on LambdaVision's lead indication.

TypeEmerging player
Description

ProQR Therapeutics develops RNA-editing therapies (AOC platform) for inherited retinal diseases including RP and Leber congenital amaurosis. It is an emerging peer because its genotype-specific approach competes for portions of the RP market that LambdaVision's genotype-agnostic protein implant would otherwise address.

6SparingVision
TypeEmerging player
Description

SparingVision is a French clinical-stage biotech developing gene therapies (SPVN06, SPVN20) targeting RP and dry AMD. It is an emerging peer because it is pursuing mutation-agnostic gene therapy approaches for RP that overlap directly with LambdaVision's lead indication and could reach patients before a protein-based implant is approved.

TypeEmerging player
Description

GenSight Biologics develops gene therapies for retinal and CNS disorders, with Lumevoq approved in EU/UK for Leber hereditary optic neuropathy (LHON) and GS030 in development for RP. It is an emerging peer in the broader retinal-disease treatment space where LambdaVision's protein implant would compete.

TypeOthers
Description

Varda Space Industries is building in-space pharmaceutical manufacturing and reentry capability, having successfully returned the first space-manufactured drug product. It is an "others" peer because it operates the same low-Earth-orbit biomanufacturing thesis as LambdaVision but in small-molecule formulation rather than protein-based therapeutics, signaling the broader commercial validation of orbital drug production.

TypeBroad incumbent
Description

Regeneron commercializes Eylea (aflibercept) and Eylea HD, the leading anti-VEGF therapies for wet AMD and other retinal diseases. It is a broad incumbent because, while not pursuing a restorative implant, it dominates the standard-of-care market that LambdaVision's protein implant would either complement or partially substitute in the AMD patient population.

TypeBroad incumbent
Description

Roche/Genentech markets Lucentis (ranibizumab) and Vabysmo (faricimab), the leading anti-VEGF therapies for wet AMD and related retinal conditions. It is a broad incumbent that defines the current treatment paradigm for the AMD market LambdaVision aims to enter with a restorative implant for advanced disease.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LambdaVision

Ophthalmology Medical Deviceslambdavision.com

LambdaVision is a pre-clinical biotechnology company developing the first protein-based artificial retina, manufactured in microgravity aboard the International Space Station via a patented layer-by-layer bacteriorhodopsin process, to restore vision in patients with retinitis pigmentosa and age-related macular degeneration.

What LambdaVision does

LambdaVision is a privately held, pre-clinical-stage biotechnology company founded in 2009 at the UConn Technology Incubator Program that is developing the first protein-based artificial retina to restore meaningful vision in patients blinded by advanced retinal degenerative diseases, principally retinitis pigmentosa (RP) and, subsequently, age-related macular degeneration (AMD). The company's core technology is a layer-by-layer (LbL) thin-film process that alternates the light-activated protein bacteriorhodopsin with a polymer on a synthetic-fiber membrane to build a 200-layer implant that absorbs incident light and stimulates remaining retinal neural circuitry without requiring external power, electrodes, or bulky hardware. The process is patent-protected (USPTO worldwide patent US20200054441A1) and has been validated across nine missions to the International Space Station in partnership with Space Tango using automated CubeLab hardware, where microgravity conditions deliver superior layer uniformity, optical clarity, and material efficiency versus Earth-based production. The company is led by CEO Nicole L. Wagner, PhD (a UConn co-founder of the technology), CSO Jordan A. Greco, PhD, and founder Dr. Robert R. Birge, with a board that includes seasoned biotech operators and the Connecticut Innovations investor.

LambdaVision has no commercial product and is pre-revenue. Current revenue mechanics consist entirely of non-dilutive grant funding from NASA (SBIR Phase II, InSPA Phase 2, $5M Commercialization Award), the National Science Foundation, the National Eye Institute/NIH, and the Connecticut Bioscience Innovation Fund (~$12M cumulatively from NASA/ISS National Lab), supplemented by priced equity rounds including a 2018 Series A from Connecticut Innovations, a 2024 first seed closing led by Aurelia Foundry Fund, and a $7M seed round in November 2025 co-led by Seven Seven Six and Aurelia Foundry Fund with Seraphim Space, providing stated runway into 2027. Total funding raised to date is approximately $22-23M. Future revenue is expected to come from one-time hardware sales of the artificial retina implant to retinal specialists and academic medical centers (e.g., Yale School of Medicine with Dr. Luciano V. Del Priore as an early clinical champion), with longer-term optionality from licensing the underlying LbL protein film platform for adjacent applications in biosensors, optical systems, tissue engineering, and drug delivery.

The go-to-market motion is a hybrid of strategic co-development partnerships (Space Tango, Helogen, Starlab/Voyager, Vast) for orbital manufacturing and future direct-to-clinical-site field sales for the implant itself, supported by PR/earned media, content marketing, conference presence, and event-driven investor cultivation (CEO speaking at Payload Investors Summit November 2025). To secure post-ISS manufacturing redundancy ahead of the 2030 ISS retirement, the company has pre-booked payload slots on three independent commercial space infrastructure platforms — Starlab Space, Vast's Haven-1 and successors, and Helogen's HEL-IOS — while continuing IND-enabling preclinical studies targeted at advanced retinitis pigmentosa as the first clinical indication and age-related macular degeneration as the second.

LambdaVision firmographics

Firmographics
Name
LambdaVision
Legal name
LambdaVision, Inc.
Website
https://lambdavision.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
LambdaVision is a pre-clinical biotechnology company developing the first protein-based artificial retina, manufactured in microgravity aboard the International Space Station via a patented layer-by-layer bacteriorhodopsin process, to restore vision in patients with retinitis pigmentosa and age-related macular degeneration.
Ownership category
akta.pro rank

LambdaVision industry classification

Industry
Product category
Ophthalmology Medical Devices
NAICS
Ophthalmic Goods Manufacturing (339115)
SIC
Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAHAJAJ
Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAE
Retina & Vitreous Specialists

Keywords

  • Protein-based artificial retina
  • Retinal degenerative diseases
  • Microgravity biomanufacturing
  • Layer-by-layer thin films
  • Bacteriorhodopsin implants

Where LambdaVision is headquartered

Location

Headquarters

HQ city
Woodbridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

LambdaVision business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Non-dilutive government and foundation grants: Pre-clinical funding sourced from NASA (SBIR Phase II, InSPA commercialization awards, ~$12M from NASA and ISS National Lab), the National Science Foundation, and the National Eye Institute/NIH; these funds support preclinical studies, scale-up, and ISS mission costs.
  2. Equity (venture capital) financing: Pre-revenue company; capital is raised through priced equity rounds (notably a $7M seed round co-led by Seven Seven Six and Aurelia Foundry Fund in November 2025, and an earlier Series A from Connecticut Innovations in 2018) used to fund operations through IND-enabling studies and a planned future Series A.
  3. Future product sales of protein-based artificial retina implant: Planned future commercial revenue from sale of the protein-based artificial retina as a one-time implant to treat advanced retinitis pigmentosa and later age-related macular degeneration, following regulatory clearance and clinical trials.
  4. Future platform licensing for adjacent applications: Longer-term licensing/royalty potential from the LbL protein film platform for biosensors, optical systems, tissue engineering, and drug delivery applications once the core artificial retina is commercialized.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

LambdaVision product offering

Product offering

Core offering

LambdaVision develops an investigational protein-based artificial retina implant produced by layer-by-layer deposition of approximately 200 thin films of the light-activated protein bacteriorhodopsin alternating with a polymer on a synthetic-fiber membrane. Manufacturing is conducted in microgravity aboard the International Space Station using Space Tango CubeLab hardware to achieve superior layer uniformity, optical clarity, and material efficiency, with the implant designed to restore meaningful vision in patients blinded by advanced retinitis pigmentosa and age-related macular degeneration.

Differentiator

Problem solved

Functional benefit

Products and services

  • Protein-Based Artificial Retina (investigational implant for retinitis pigmentosa and AMD)

Quantifiable outcome

  • 9 of 9 ISS missions successfully produced multiple 200-layer protein thin films in microgravity
  • +4 more outcomes

Companies that use LambdaVision

Customer profile

Segments3 records

Ideal customer profiles4 records

LambdaVision technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

LambdaVision partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered strategic (post-iss mou), flagship (first mission outside the iss), flagship (post-iss commercial manufacturing anchor), flagship (starlab lead; nyse: voyg), flagship (long-running implementation partner), flagship (multi-program government partner) and strategic (clinical advisor).

  • Vaststrategic (post-iss mou)Strategic or Co-development Partner · 24 June 2026Signed a memorandum of understanding on June 24, 2026 with Vast to continue and expand LambdaVision's biomedical research on Vast's Haven-1 and future commercial space stations, after the ISS is retired at the end of the decade. Vast's partner network also includes the Sanford Stem Cell Institute at UC San Diego, Auxilium Biotechnologies, and BioOrbit.
  • Helogen Corporationflagship (first mission outside the iss)Strategic or Co-development Partner · 18 May 2026Strategic partnership announced May 18, 2026 to launch LambdaVision's first orbital manufacturing mission outside the ISS aboard Helogen's fully autonomous HEL-IOS™ manufacturing system in low-Earth orbit, targeted for the second half of 2026. Validates the full operational chain for GMP-compliant production of the artificial retina in LEO, including ground preparation, flight qualification, in-orbit manufacturing, sample return, and custody transfer. Connection initiated through the 2023 Boryung Humans in Space challenge. Helogen also won the 2025 NASA TechLeap Prize.
  • Starlab Space LLCflagship (post-iss commercial manufacturing anchor)Strategic or Co-development Partner · 24 February 2026Reservation agreement signed February 24, 2026 for payload slots and commercial space on Starlab's next-generation commercial space station. Supports LambdaVision's transition from research demonstration to scalable, sustainable manufacturing in low-Earth orbit ahead of the 2030 ISS retirement. Starlab is a U.S.-led global JV among Voyager Technologies, Airbus, Mitsubishi Corporation, MDA Space, Palantir Technologies, and Space Applications Services, with strategic partners Hilton, Journey, Northrop Grumman, and The Ohio State University.
  • Voyager Technologiesflagship (starlab lead; nyse: voyg)Strategic or Co-development Partner · 24 February 2026Lead joint-venture partner in Starlab Space; partnered with LambdaVision through the Starlab payload reservation announced February 24, 2026 to provide commercial space station access in low-Earth orbit. Seraphim Space is an investor in both LambdaVision and Voyager, enabling portfolio collaboration.
  • Space Tangoflagship (long-running implementation partner)Implementation/ SI/ Consulting PartnerLong-term implementation partner for LambdaVision's ISS missions; provides automated CubeLab hardware on the ISS U.S. National Laboratory. The partnership has secured >$7.7M in funding from NASA and supported all 9 of LambdaVision's ISS investigations refining the LbL manufacturing process. Space Tango is headquartered in Lexington, KY.
  • NASAflagship (multi-program government partner)OthersLong-standing funding and program partner: NASA SBIR Phase II awards, InSPA commercialization awards, the September 2025 Phase 2 InSPA award, and access to the ISS U.S. National Laboratory have collectively provided roughly $12M in non-dilutive funding and 9 ISS missions. NASA's programs underpin LambdaVision's IND-enabling and GMP manufacturing scale-up.
  • Yale School of Medicine (Ophthalmology)strategic (clinical advisor)Implementation/ SI/ Consulting PartnerClinical research collaboration with Dr. Luciano V. Del Priore, MD, PhD — Robert R. Young Professor of Ophthalmology and Visual Science, Chair of Ophthalmology at Yale School of Medicine, and Chief of Ophthalmology at Yale New Haven Hospital — supporting the artificial retina's preclinical and clinical translation.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

LambdaVision competitors and assessment

Company assessment

Direct peers

  • Pixium Vision: Pixium Vision developed the PRIMA photovoltaic sub-retinal prosthesis for advanced dry AMD, gaining EU/UK CE marking. It is the most direct retinal implant competitor to LambdaVision, using a different (electronic photovoltaic) mechanism but targeting the same RP/AMD patient population with a surgically implanted retinal prosthesis.
  • Second Sight Medical Products (now Nano Precision Medical): Second Sight developed and commercialized the Argus II epiretinal prosthesis, the first FDA-approved retinal implant for RP. After discontinuing the Argus business, the company refocused as Nano Precision Medical with a drug delivery platform. Argus II is the historical benchmark for retinal prosthesis regulatory and commercial pathways that LambdaVision will be compared against.
  • Bionic Vision Technologies: Bionic Vision Technologies is an Australian company developing a suprachoroidal retinal prosthesis for patients with retinitis pigmentosa. It is a direct peer because it is pursuing a retinal implant for the same RP indication with a similar surgical implantation approach, though using electrode-based rather than protein-based stimulation.

Emerging players

  • jCyte: jCyte is developing a stem cell-based therapy (jCell) for retinitis pigmentosa aimed at preserving and restoring vision through paracrine effects on remaining photoreceptors. It is an emerging peer because it targets the same RP patient population via an alternative mechanism (cell therapy rather than prosthesis) and represents potential competitive pressure on LambdaVision's lead indication.
  • ProQR Therapeutics: ProQR Therapeutics develops RNA-editing therapies (AOC platform) for inherited retinal diseases including RP and Leber congenital amaurosis. It is an emerging peer because its genotype-specific approach competes for portions of the RP market that LambdaVision's genotype-agnostic protein implant would otherwise address.
  • SparingVision: SparingVision is a French clinical-stage biotech developing gene therapies (SPVN06, SPVN20) targeting RP and dry AMD. It is an emerging peer because it is pursuing mutation-agnostic gene therapy approaches for RP that overlap directly with LambdaVision's lead indication and could reach patients before a protein-based implant is approved.
  • GenSight Biologics: GenSight Biologics develops gene therapies for retinal and CNS disorders, with Lumevoq approved in EU/UK for Leber hereditary optic neuropathy (LHON) and GS030 in development for RP. It is an emerging peer in the broader retinal-disease treatment space where LambdaVision's protein implant would compete.

Others

  • Varda Space Industries: Varda Space Industries is building in-space pharmaceutical manufacturing and reentry capability, having successfully returned the first space-manufactured drug product. It is an "others" peer because it operates the same low-Earth-orbit biomanufacturing thesis as LambdaVision but in small-molecule formulation rather than protein-based therapeutics, signaling the broader commercial validation of orbital drug production.

Broad incumbents

  • Regeneron Pharmaceuticals: Regeneron commercializes Eylea (aflibercept) and Eylea HD, the leading anti-VEGF therapies for wet AMD and other retinal diseases. It is a broad incumbent because, while not pursuing a restorative implant, it dominates the standard-of-care market that LambdaVision's protein implant would either complement or partially substitute in the AMD patient population.
  • Roche (Genentech): Roche/Genentech markets Lucentis (ranibizumab) and Vabysmo (faricimab), the leading anti-VEGF therapies for wet AMD and related retinal conditions. It is a broad incumbent that defines the current treatment paradigm for the AMD market LambdaVision aims to enter with a restorative implant for advanced disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

LambdaVision social profiles

Digital presence

LambdaVision financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LambdaVision leadership team

Management profile

Number of profiles

Profiles7 records

LambdaVision funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LambdaVision M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LambdaVision

What does LambdaVision do?

LambdaVision develops an investigational protein-based artificial retina implant produced by layer-by-layer deposition of approximately 200 thin films of the light-activated protein bacteriorhodopsin alternating with a polymer on a synthetic-fiber membrane. Manufacturing is conducted in microgravity aboard the International Space Station using Space Tango CubeLab hardware to achieve superior layer uniformity, optical clarity, and material efficiency, with the implant designed to restore meaningful vision in patients blinded by advanced retinitis pigmentosa and age-related macular degeneration.

Is LambdaVision a public or private company?

LambdaVision is a private company. It is classified as venture growth investor backed and is currently operating.

When was LambdaVision founded?

LambdaVision was founded in 2009. It employs 11 to 50 people.

Where is LambdaVision based?

LambdaVision is headquartered in Woodbridge, United States, in the North America region.

How does LambdaVision make money?

Four revenue lines are on record. Non-dilutive government and foundation grants are the primary driver. The others are equity (venture capital) financing, future product sales of protein-based artificial retina implant and future platform licensing for adjacent applications.

Who are LambdaVision's main competitors?

Direct peers on record are Pixium Vision, Second Sight Medical Products (now Nano Precision Medical) and Bionic Vision Technologies. Emerging players are jCyte, ProQR Therapeutics, SparingVision and GenSight Biologics. Varda Space Industries is listed as an others. Broad incumbents are Regeneron Pharmaceuticals and Roche (Genentech).

Does LambdaVision have an API?

No public API is recorded for LambdaVision.

What industry is LambdaVision in?

LambdaVision's product category is Ophthalmology Medical Devices. Its primary akta.pro industry code is HLAHAJAJ, Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades), with a secondary code of HLAKAKAE, Retina & Vitreous Specialists. Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageLambdaVision Advances Space-Based Manufacturing With Its First Mission Beyond the ISSLambdaVision announced an October 2026 mission with Helogen to test its bacteriorhodopsin protein beyond the ISS, marking its first flight outside the station. The mission will use Helogen's autonomous HEL-IOS platform to evaluate the protein for its artificial retina, building on nine prior ISS trips.MorningstarLambdaVision Advances Space-Based Manufacturing With Its First Mission Beyond the ISSLambdaVision announced an October 2026 mission with Helogen to test its bacteriorhodopsin protein beyond the ISS, marking its first flight outside the station. The mission will use Helogen's autonomous HEL-IOS platform to evaluate the protein and gather data for future quality controls in low-Earth orbit.ScienceDreams of making drugs and tissues in space get closer to realityA Science article reports that falling launch costs and mature orbital labs are enabling startups like Varda Space Industries, LambdaVision and BioOrbit to manufacture drugs, protein films and organoids in microgravity. Launch costs per kilogram have fallen from over $15,000 in 2000 to under $4,000 in 2025, projected to drop another 50% by 2030. Varda has seven flights scheduled for 2027 and 10 for 2028.Ophthalmology TimesArtificial retina production among projects headed to International Space StationLambdaVision is launching a payload to the International Space Station via Northrop Grumman's NG-20 mission to test in-space manufacturing of artificial retinas using bacteriorhodopsin protein. The biotechnology startup aims to leverage microgravity to improve implant quality and scalability for treating retinitis pigmentosa. This investigation builds on previous ISS missions that have already yielded ten test retinas returned to Earth.PR NewswireBiotech Startup Turns to Space to Manufacture Artificial Retinas for Treating BlindnessLambdaVision is manufacturing artificial retinas on the ISS to improve uniformity and reduce waste. The company has conducted nine investigations and aims to treat over 200 million people with macular degeneration. Its next ISS launch is planned later this year, with future commercial space stations as a target.Business Wire BlogLambdaVision and Vast Sign Agreement to Advance Space-Based Manufacturing of Protein-Based Artificial Retina and Microgravity BioprocessesLambdaVision, a pre-clinical-stage biotech company, signed a memorandum of understanding with Vast to support future research and manufacturing aboard Vast's Haven-1 and future commercial space stations. The collaboration builds on LambdaVision's nine successful International Space Station missions demonstrating that microgravity can improve production of multilayer protein thin films for its protein-based artificial retina designed to treat retinal degenerative diseases. LambdaVision, which recently closed a $7M seed funding round and has secured approximately $23M in total funding to date, is expanding its commercial low-Earth orbit strategy as it advances toward clinical development.3D Printing IndustryArtificial Retinas Manufactured in Orbit Show Superior Results, Offering New Hope for Incurable Vision LossConnecticut-based biotech LambdaVision has spent nearly a decade manufacturing artificial retinas on the International Space Station, achieving superior layer uniformity, optical clarity, and material efficiency compared to Earth-based production due to the absence of gravity-driven sedimentation and buoyancy effects. After nine ISS investigations conducted in partnership with Space Tango, the company has refined its automated CubeLab-based manufacturing system and demonstrated consistent outperformance across all measured metrics. The company is planning a tenth ISS mission in 2026 focused on scaling production volume, targeting age-related macular degeneration and retinitis pigmentosa—conditions affecting more than 200 million people worldwide—and has reserved capacity on the future Starlab commercial station to transition from the ISS.VoxelMattersLambdaVision preparing to scale 3D printed retina production in orbitConnecticut-based biotech startup LambdaVision is preparing its tenth investigation aboard the International Space Station in 2026 to scale the volume production of protein-based artificial retinas. The company has partnered with Space Tango and secured NASA funding to utilize microgravity for manufacturing implants with superior uniformity and quality compared to Earth-based methods. LambdaVision has also reserved capacity on the commercial Starlab station to ensure continuity of in-orbit manufacturing as the ISS approaches retirement.BioSpaceLambdaVision and Helogen Partner to Advance Space-Based Biomaterial ManufacturingLambdaVision and Helogen announced a partnership to launch a joint orbital manufacturing mission of LambdaVision's artificial retina protein aboard Helogen's autonomous system in low-Earth orbit, targeted for launch in the second half of 2026. The mission will validate operational frameworks for GMP-compliant space production, building on LambdaVision's prior ISS missions. The partnership aims to advance commercialization of the artificial retina for retinal degenerative diseases.openPR.comAnalysis of Key Market Segments Driving the Artificial Eye MarketThe artificial eye market is projected to reach $3.16 billion by 2030, growing at a 7.8% CAGR, driven by 3D printing adoption, customized prosthetics demand, and material science breakthroughs. In February 2024, United Ocular acquired Eye Prosthetics of Utah to strengthen its ocular prosthetics capabilities, while in May 2024, LambdaVision Inc. completed a seed funding round for preclinical research on protein-based artificial retina implants using bacteriorhodopsin technology.